MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Waters Corporation Operating Income 2011-2025 | WAT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Waters Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 292 M | 264 M | 873 M | 822 M | 645 M | 708 M | 740 M | 662 M | 625 M | 567 M | 518 M | 517 M | 511 M | 529 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 873 M | 264 M | 591 M |
Quarterly Operating Income Waters Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 192 M | 188 M | 152 M | - | 211 M | 189 M | 134 M | - | 179 M | 200 M | 174 M | - | 192 M | - | 195 M | 262 M | 192 M | 196 M | 171 M | 264 M | 158 M | 155 M | 68.3 M | 236 M | 173 M | 178 M | 121 M | 245 M | 172 M | 179 M | 144 M | 231 M | 159 M | 154 M | 119 M | 208 M | 152 M | 152 M | 113 M | 181 M | 136 M | 130 M | 120 M | 172 M | 139 M | 118 M | 88.8 M | 176 M | 119 M | 113 M | 109 M | 159 M | 122 M | 120 M | 110 M | 165 M | 127 M | 121 M | 116 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 264 M | 68.3 M | 161 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.36 | -4.05 % | $ 176 M |  China |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 17.05 | -2.15 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.63 | -2.11 % | $ 2.07 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 221.54 | -1.96 % | $ 40.2 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.85 | 2.32 % | $ 1.08 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Danaher Corporation
DHR
|
4.86 B | $ 227.08 | -2.28 % | $ 166 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.92 | -6.58 % | $ 338 M | Israel |
 |
DexCom
DXCM
|
598 M | $ 66.91 | -2.94 % | $ 25.8 B | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 20.44 | 3.23 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 105.26 | 4.46 % | $ 4.15 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.59 | -25.21 % | $ 115 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.58 | 0.21 % | $ 18.8 B | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.34 | -2.96 % | $ 9.98 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 27.13 | 0.26 % | $ 820 M | USA |
 |
Guardant Health
GH
|
-444 M | $ 102.09 | 0.7 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.6 | -1.52 % | $ 20 B |  Niderland |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 134.29 | -1.58 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 192.57 | -0.96 % | $ 9.89 B | USA |
 |
Quotient Limited
QTNT
|
-82.7 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 182.21 | 0.35 % | $ 20.2 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 7.94 | -1.0 % | $ 1.03 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 263.51 | -0.46 % | $ 22.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 186.28 | -1.92 % | $ 15.4 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 701.07 | -0.91 % | $ 57.8 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 66.11 | 4.76 % | $ 4.57 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 139.44 | -2.4 % | $ 42.4 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.55 | -1.07 % | $ 5.86 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 7.59 | 2.29 % | $ 475 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
-124 M | $ 7.26 | -0.62 % | $ 658 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 5.47 | -7.6 % | $ 2.94 M | USA |